Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis.
Emerging evidence has implicated reactive oxygen species (ROS) in the pathogenesis of inflammatory bowel disease (IBD). Although intestinal epithelial cells produce the ROS-neutralizing enzyme superoxide dismutase (SOD), the protein and activity levels of copper/zinc (Cu/Zn) and manganese (Mn) SOD are perturbed in inflamed tissues of IBD patients. Thus we investigated the ability of MnSOD from Streptococcus thermophilus to reduce colitis symptoms in interleukin (IL) 10-deficient mice using Lactobacillus gasseri as a delivery vehicle. Cohorts of 13-15 IL-10-deficient mice were left untreated or supplemented with native L. gasseri or L. gasseri expressing MnSOD for 4 wk. Colonic tissue was collected and inflammation was histologically scored. The presence of innate immune cells was investigated by immunohistochemistry and the host antioxidant response was determined by quantitative PCR. It was demonstrated that L. gasseri was stably maintained in mice for at least 3 days. L. gasseri producing MnSOD significantly reduced inflammation in IL-10-deficient mice compared with untreated controls (P < 0.05), whereas the anti-inflammatory effects of both native and MnSOD producing L. gasseri were more pronounced in males. The anti-inflammatory effects of L. gasseri were associated with a reduction in the infiltration of neutrophils and macrophages. Transcripts of antioxidant genes were equivalent in colonic tissues obtained from control and probiotic-treated IL-10-deficient mice. This study demonstrates that L. gasseri producing MnSOD has significant anti-inflammatory activity that reduces the severity of colitis in the IL-10-deficient mouse.
Carroll
Ian M
IM
Dept. of Genetics, CB7264, Univ. of North Carolina, Chapel Hill, NC 27599, USA.
Andrus
Jason M
JM
Bruno-Bárcena
José M
JM
Klaenhammer
Todd R
TR
Hassan
Hosni M
HM
Threadgill
Deborah S
DS
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003092:Colitis / Q000188:drug therapy* / Q000473:pathology; D003106:Colon / Q000473:pathology; D051546:Cyclooxygenase 2 / Q000378:metabolism; D004195:Disease Models, Animal; D007150:Immunohistochemistry; D016753:Interleukin-10 / Q000172:deficiency; D007778:Lactobacillus / Q000201:enzymology*; D051379:Mice; D009195:Peroxidase / Q000378:metabolism; D019936:Probiotics / Q000627:therapeutic use*; D013047:Specific Pathogen-Free Organisms; D013482:Superoxide Dismutase / Q000096:biosynthesis* / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D016753:Interleukin-10; D009195:Peroxidase; D051546:Cyclooxygenase 2; D013482:Superoxide Dismutase